Event-free survival by transplantation status. The response analysis is based on the intent-to-treat population, and includes data from the 3 patients who withdrew from treatment before completing the first cycle of therapy (2 patients withdrew consent for personal reasons, 1 because of early toxicity–cytopenia). The median event-free survival times have not been reached for the transplantation or nontransplantation groups, with an actuarial 2-year event-free survival of 85.2% and 75.2%.